文献速递免疫规划传染病防控与疫情报告

RSV/hMPV联合病毒样颗粒疫苗在60-85岁成人中的IIa期随机临床试验

A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60-85 years of age.
PubMed 文献 · Vaccine · 2026-03-04

本研究为IIa期随机试验,纳入264名60-85岁健康成人(含稳定慢性病者),按2:2:1随机接受无佐剂IVX-A12、含MF59佐剂IVX-A12或安慰剂单剂肌注。结果显示IVX-A12耐受性良好,可诱导RSV和hMPV特异性中和抗体反应,但添加MF59未增强抗体应答或延长持续时间。

要点

  • IVX-A12在60-85岁成人中耐受性良好,局部和全身不良反应多为轻至中度。
  • 接种后28天,RSV A和B中和抗体分别升高5-6倍和3-4倍,hMPV A和B均升高2-3倍。
  • 添加MF59佐剂未增强抗体应答或延长抗体持续时间。

核心结论

  • IVX-A12在60-85岁成人中耐受性良好,并诱导RSV和hMPV特异性抗体反应,证明RSV/hMPV联合疫苗的可行性。

研究设计与样本

  • IIa期随机临床试验,264名60-85岁健康成人(含稳定慢性病者)按2:2:1随机接受无佐剂IVX-A12(150 μg RSV/150 μg hMPV)、含MF59佐剂IVX-A12或安慰剂单剂肌注,按年龄分层(60-69/70-85岁),随访至接种后365天。

主要发现

  • 总体264人接受IVX-A12(n=211)或安慰剂(n=53); solicited不良反应轻至中度,无佐剂组报告率57.3%(59/103),含MF59组75.0%(81/108),安慰剂组37.7%(20/53)。
  • 接种后28天,IVX-A12(±MF59)组RSV A和B中和抗体分别升高5-6倍和3-4倍,hMPV A和B均升高2-3倍。
  • 接种后365天,除hMPV A外,IVX-A12组中和抗体仍高于基线且高于安慰剂组。
  • 添加MF59未增强抗体应答或延长持续时间;两个年龄层安全性和免疫原性相似。

临床怎么用

  • IVX-A12可作为老年人RSV和hMPV联合预防的候选疫苗,但需进一步III期试验验证临床保护效力。

局限性

  • 本研究为IIa期试验,样本量有限,未评估临床终点(如LRTD发生率)。
  • 未报告对RSV/hMPV感染的保护效力数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV)- and human metapneumovirus (hMPV)-associated lower respiratory tract disease (LRTD) contributes substantially to morbidity and mortality in older adults. IVX-A12 is an investigational combination vaccine comprised of two virus-like particles computationally designed to elicit immune responses against RSV and hMPV. In a Phase I randomized trial, IVX-A12 was well tolerated and elicited RSV- and hMPV-specific neutralizing antibody (nAb) responses in adults 60-75 years of age. METHODS: In this Phase IIa trial, healthy adults 60-85 years of age, including participants with stable, chronic conditions, were randomized 2:2:1 to receive one intramuscular dose of IVX-A12 (150 μg RSV/150 μg hMPV) with/without MF59® (oil-in-water adjuvant), or placebo (diluent), stratified by age group (60-69/70-85 years). Safety and immunogenicity were assessed through 365 days post-vaccination. RESULTS: Overall, 264 participants received IVX-A12 (n = 211) or placebo (n = 53). Solicited adverse reactions were mild-to-moderate in severity and were reported by 57.3% (n = 59/103), 75.0% (n = 81/108), and 37.7% (n = 20/53) of recipients of unadjuvanted IVX-A12, IVX-A12 + MF59®, and placebo, respectively. IVX-A12 induced increases in nAbs against RSV and hMPV. From baseline to Day 28, in IVX-A12 (±MF59®) recipients, nAbs against RSV A and B increased 5-6- and 3-4-fold, respectively, and nAbs against hMPV A and B both increased 2-3-fold. In IVX-A12 recipients, all except hMPV A nAbs remained above baseline levels at Day 365 and were higher than in placebo recipients. Addition of MF59® to IVX-A12 did not boost antibody responses nor increase their duration. Safety and immunogenicity were similar between the stratified age groups. CONCLUSIONS: IVX-A12 was well tolerated and induced RSV- and hMPV-specific antibody responses in adults 60-85 years of age. This trial demonstrated the feasibility of an RSV/hMPV combination vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Davis M, Shapiro C, Ciarlet M, et al. A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60-85 years of age. Vaccine. 2026. PMID: 41785514. doi:10.1016/j.vaccine.2026.128345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。